{
  "paper_metadata": {
    "pmid": "33747156",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the BRCA2 variant p.Q548Q, including clinical significance, patient demographics, penetrance data, and functional information."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": null,
      "protein_notation": "p.Q548Q",
      "genomic_position": null,
      "clinical_significance": "LEVEL_2B",
      "patients": {
        "count": 1,
        "demographics": "Patient 14, age 50, sex not specified",
        "phenotype": "Pancreatic neuroendocrine tumor (PNET)"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P14",
          "age_at_evaluation": 50,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "unknown",
          "affected_status": "affected",
          "phenotype_details": "Pancreatic neuroendocrine tumor",
          "evidence_sentence": "Altogether, two potentially actionable genomic alterations in BRCA2 (p.Q548Q) and neurofibromin 1 (NF1; p.Q1188X) were detected in patient nos. 14 and 8, respectively."
        }
      ],
      "functional_data": {
        "summary": "The evidence level for BRCA2 (p.Q548Q) for patients with PNET was LEVEL_2B, which was defined by OncoKB as a standard care biomarker recommended by the National Comprehensive Cancer Network (NCCN) or other expert panels as predictive of a response to a Food and Drug Administration-approved drug.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "LEVEL_2B",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The variant is associated with actionable treatment options including niraparib, olaparib, rucaparib, and talazoparib.",
      "key_quotes": [
        "The evidence level for BRCA2 (p.Q548Q) for patients with PNET was LEVEL_2B, which was defined by OncoKB as a standard care biomarker recommended by the National Comprehensive Cancer Network (NCCN, https://education.nccn.org/) or other expert panels as predictive of a response to a Food and Drug Administration-approved drug."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "The extraction was straightforward as the paper provided clear information on the BRCA2 variant."
  }
}